Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)

Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04530175

Acronym

MARC

Enrollment

Registered

2020-08-28

Start date

2021-02-02

Completion date

2021-07-07

Last updated

2022-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease

Keywords

hemodialysis, modeling, Citrate anticoagulation

Brief summary

The primary purpose of this study is to validate a mathematical modeling of treatment by intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing calcium

Detailed description

The only visit to the study will be carried out during a usual dialysis session in the intensive care unit of Clermont-Ferrand University Hospital. In addition to the usual care, 2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.

Interventions

OTHERblood sampling

2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major patient; * Man or woman ; * Treated with intermittent hemodialysis for chronic renal failure; * In whom intermittent hemodialysis with citrate solution for regional anticoagulation is indicated; * Affiliated with a social security scheme; * Having given a signed agreement after detailed explanation of the protocol on the basis of the information sheet and likely to comply with it

Exclusion criteria

* Severe hepato-cellular insufficiency (PT \<50%, INR\> 1.5 without anticoagulant); * Hemoglobin level \<7 g / dL * Presenting a psychiatric pathology or cognitive impairment rendering him unable to give informed consent; * Persons under guardianship, curatorship, deprived of liberty or safeguard of justice * Pregnant or breastfeeding women * Patient's refusal to participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
Ionized calcium level	day 0	measured at dialyzer inlet, in mmol/L
Total calcium level	day 0	measured at dialyzer inlet, in mmol/L
Total citratemia	day 0	measured at dialyzer inlet, in mmol/L

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026